

S/N 09/150,813

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: David J. Grainger et al.

Examiner: Joseph F. Murphy, Ph.D.

Serial No.: 09/150,813

Group Art Unit: 1646

Filed: September 11, 1998

Docket: 295.027US1

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN
INFLAMMATORY RESPONSE

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant has reviewed the Office Action mailed on November 29, 2000. Please amend the above-identified patent application as follows.

In the Claims

Please substitute the claim set in the appendix entitled "Clean Version of Pending Claims" for the previously pending claim set. Specific amendments to individual claims are detailed in the following marked up set of claims.

Please amend the claims as follows:

55. (Amended) The method of claim 20, 22 or 34, wherein the [CXC] chemokine is interleukin 8 (IL-8), interferon inducible protein 10 (IP-10), platelet factor-4 (PF-4), stromal cell-derived factor-1 (SDF-1 α), neutrophil activating protein-2 (NAP-2), growth regulated oncogene alpha (GRO α), GRO β , GRO γ or epithelial neutrophil activating peptide-78 (ENA78).

56. (Amended) The method of claim [17] 54, wherein the CXC chemokine is interferon inducible protein 10 (IP-10), platelet factor-4 (PF-4), stromal cell-derived factor-1 (SDF-1 α), growth regulated oncogene alpha (GRO α), GRO β , GRO γ or epithelial neutrophil activating peptide-78 (ENA78).

Remarks

Reconsideration and withdrawal of the rejections of the claims, in view of the remarks presented herein, is respectfully requested. Claims 17, 20-22, 24-28, 31-35, 40-45, 48-50, and 52-62 are pending. The amendments to claims 55-56 are supported by page 29, line 8 through page 30, line 5 of the specification.

21/c
JGJ
6/9/01